NASDAQ:MOTS - Motus GI Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.19 -1.02 (-12.42 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$8.21
Today's Range$7.13 - $8.19
52-Week Range$3.75 - $10.66
Volume143,900 shs
Average Volume84,188 shs
Market Capitalization$128.45 million
P/E Ratio-6.16
Dividend YieldN/A
BetaN/A
Motus GI logoMotus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.

Receive MOTS News and Ratings via Email

Sign-up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MOTS
CUSIPN/A
Phone786-459-1831

Debt

Debt-to-Equity RatioN/A
Current Ratio12.32
Quick Ratio12.31

Price-To-Earnings

Trailing P/E Ratio-6.16
Forward P/E Ratio-6.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales11,252.35
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees39
Outstanding Shares15,650,000
Market Cap$128.45

The Truth About Cryptocurrencies

Motus GI (NASDAQ:MOTS) Frequently Asked Questions

What is Motus GI's stock symbol?

Motus GI trades on the NASDAQ under the ticker symbol "MOTS."

How were Motus GI's earnings last quarter?

Motus GI Holdings Inc (NASDAQ:MOTS) released its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.09. The firm had revenue of $0.01 million for the quarter. View Motus GI's Earnings History.

What price target have analysts set for MOTS?

3 Wall Street analysts have issued 12 month target prices for Motus GI's shares. Their predictions range from $7.00 to $12.00. On average, they expect Motus GI's share price to reach $9.6667 in the next year. This suggests a possible upside of 34.4% from the stock's current price. View Analyst Ratings for Motus GI.

What is the consensus analysts' recommendation for Motus GI?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Motus GI's key competitors?

Who are Motus GI's key executives?

Motus GI's management team includes the folowing people:
  • Mr. Mark Pomeranz, CEO & Director (Age 56)
  • Mr. Andrew Lawrence Taylor, Chief Financial Officer (Age 47)
  • Mr. Todd Van Emburgh, Pres
  • Ms. Hagit Ephrath, VP Health Economics, Regulatory & Clinical Affairs
  • Gil Balog, Gen. Mang. of Israel

When did Motus GI IPO?

(MOTS) raised $21 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 3,500,000 shares at a price of $5.00-$7.00 per share. Piper Jaffray served as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

When does the company's lock-up period expire?

Motus GI's lock-up period expires on Monday, August 13th. Motus GI had issued 3,500,000 shares in its IPO on February 14th. The total size of the offering was $17,500,000 based on an initial share price of $5.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Has Motus GI been receiving favorable news coverage?

Press coverage about MOTS stock has trended somewhat positive on Monday, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Motus GI earned a daily sentiment score of 0.15 on Accern's scale. They also gave media headlines about the company an impact score of 46.05 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Motus GI?

Shares of MOTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Motus GI's stock price today?

One share of MOTS stock can currently be purchased for approximately $7.19.

How big of a company is Motus GI?

Motus GI has a market capitalization of $128.45 million and generates $10,000.00 in revenue each year. The company earns $-13,200,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Motus GI employs 39 workers across the globe.

How can I contact Motus GI?

Motus GI's mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The company can be reached via phone at 786-459-1831 or via email at [email protected]


MarketBeat Community Rating for Motus GI (NASDAQ MOTS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about Motus GI and other stocks. Vote "Outperform" if you believe MOTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share (EPS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.